Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration

N/ANot Yet RecruitingNCT07221656

Mayo Clinic20 enrolled

Overview

This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Childhood Acute Lymphoblastic Leukemia Childhood Lymphoblastic Lymphoma

Interventions

Non-Interventional StudyOTHER

Non-interventional study

Eligibility

Sex: ALLMax age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Acute lymphoblastic leukemia/lymphoma being treated by the pediatric hematology team * Receiving calaspargase as part of treatment for malignancy Exclusion Criteria: * Age \> 21 years * Patients who are actively enrolled on Children's Oncology Group (COG) trial AALL1732 in an inotuzumab containing arm * Pregnancy

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Duration of therapeutic SAA

Descriptive statistics including medians and interquartile ranges will be utilized to summarize continuous variables.

Time frame: Up to 15 months

Central Contacts

Clinical Trials Referral Office

CONTACT

855-776-0015 mayocliniccancerstudies@mayo.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.